.png)
September is Gynaecological Cancer Awareness Month in the UK, and this year brings new hope. Research in 2025 revealed important gains across ovarian, cervical, womb (uterine), and rare gynecologic cancers. From smarter screenings to improved survival, especially when caught early, the outlook is evolving. For the 22,000+ women diagnosed each year in the UK, here’s what this year’s progress means for the future of care.
Key Facts
- About 22,000 women in the UK are diagnosed with gynaecological cancers each year1.
- Ovarian cancer accounts for roughly 7,400 new cases yearly, with a 5-year survival rate of 43%2.
- ~66 per cent of UK ovarian cancer cases are detected at stage III or IV, making treatment more challenging3.
- Uterine (womb) cancer has approximately 9,700 cases a year and is often diagnosed early4.
- Cervical cancer sees about 3,300 UK diagnoses annually, with a national screening programme since 19885.
- Around 99.8 per cent of cervical cancer cases are linked to high-risk HPV infection6,7.
Understanding Gynaecological Cancers
Gynaecological cancers affect the female reproductive system and include ovarian, uterine, cervical, vulval, and vaginal cancers. Ovarian cancer is the hardest to detect early and has the highest fatality rate, often presenting with vague symptoms like bloating and pelvic pain8. Uterine cancer is the most common, especially among postmenopausal women, with abnormal vaginal bleeding as a typical sign9.
Cervical cancer is largely preventable through HPV vaccination and regular screening, such as Pap smears, which catch abnormal cell changes before cancer develops6. Vulval and vaginal cancers are rare, but their incidence increases with age; symptoms include skin changes, lumps, or persistent itching in the genital area10–12.
Early diagnosis is crucial as it significantly improves treatment outcomes and survival rates.
2025 Research Highlights
New findings have deepened our understanding of gynecologic cancers, from their detection to their response to treatment.
AI Demonstrates High Accuracy in Cervical Cytology
A recent systematic review found that AI-assisted analysis of cervical cytology slides achieves approximately 94% accuracy, 95% sensitivity, and 94% specificity, on par with highly trained pathologists. AI models could improve screening efficiency and reduce diagnostic delays13.
Liquid Biopsy for Ovarian Cancer Moves Closer to Clinic
Combining circulating tumour DNA (ctDNA) with protein biomarkers such as CA125 and HE4 significantly improves sensitivity for early ovarian cancer detection, with models like EarlySEEK achieving up to 94.2% sensitivity and outperforming CA125 alone in distinguishing benign from malignant tumours14.
Immunotherapy Shows Promise in Recurrent Endometrial Cancer
PD1/PDL1 inhibition alongside chemotherapy significantly improves progression-free survival and overall survival in advanced and recurrent EC patients15. This opens treatment doors for women with few remaining options.
Early Detection: Why It Still Matters
Early detection is vital in gynaecological cancers. For ovarian cancer, outcomes are much poorer when diagnosed late. ~66% of cases are found at an advanced stage, leading to a five-year survival rate below 30%3,16. In contrast, detecting ovarian cancer early raises survival rates to over 90%17.
Tools like screening programs, advanced imaging (including MRI), and reviewing family history all play powerful roles in catching cancers earlier. Ezra’s MRI with Spine and organ-specific MRI scans can detect abnormalities in the pelvic region, including the ovaries and uterus, often before symptoms appear, helping expand treatment options and improve survival rates.
What You Can Do This Gynaecological Cancer Awareness Month
September is Gynaecological Cancer Awareness Month, an ideal time to take action and support those affected.
Get Involved
- Donate or support UK organisations like Target Ovarian Cancer or The Eve Appeal to fund vital research and support services.
- Organise a “Go Red” day at work or school to promote awareness.
- Fundraise by hosting walkathons, bake sales, or sponsored sporting events.
Spread Awareness
- Share key symptoms, infographics, or survivor stories on social media to amplify the message.
- Use hashtags like #GynaecologicalCancerAwareness, #KnowYourBody, or #CheckYourSymptoms for better reach.
- Start conversations about screening and HPV vaccinations with friends, colleagues, and loved ones to encourage prevention and early detection.
Connect to Community
- Find local or online support groups through Macmillan or The Eve Appeal.
- If experiencing symptoms, consider booking a private scan for reassurance and proactive care.
- Seek open, proactive health discussions with a GP for peace of mind and early action.
Summary
2025 has been a landmark year for gynaecological cancer research, offering renewed hope across ovarian, cervical, uterine, and rare gynaecological cancers. Advances include the implementation of AI screening, new liquid biopsy tools for earlier ovarian cancer detection, and fresh immunotherapy approaches that extend survival in advanced endometrial cancer. Community support, awareness, and access to state-of-the-art imaging and genetic tools remain vital.
If you want to be proactive about your health, why not book an Ezra MRI Scan with Spine? Our annual scan catches potential cancer earlier by leveraging AI in the screening process, making it more efficient, affordable, and faster.
Frequently Asked Questions
Can gynaecologic cancers be prevented?
Many gynaecological cancers can be prevented, especially cervical cancer, through HPV vaccination, healthy lifestyle choices, and regular screening.
Are symptoms always obvious?
Symptoms are not always obvious; some cancers present with vague or mild signs that are easy to overlook, making awareness and vigilance important.
At what age should I get screened?
Screening for cervical cancers should start at age 25 or earlier based on risk, while other cancers have targeted screening only for high-risk individuals. Discuss your options with your GP.
Can men carry a hereditary risk for gynaecologic cancers?
Men can carry a hereditary risk for gynaecologic cancers as genetic mutations like BRCA can be passed down and increase risk in female relatives.
